News & Updates

Female AYA cancer survivors: Are they at risk for adverse obstetric outcomes?

06 Aug 2024 by

Female adolescent and young adult (AYA) survivors of certain types of cancer appear to be at risk of birth rate deficits and obstetric complications, suggests a retrospective study from the UK.

Female AYA cancer survivors: Are they at risk for adverse obstetric outcomes?

06 Aug 2024

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

05 Aug 2024 by

In the treatment of women with endometriosis-associated pain, relugolix combination has a risk-benefit profile that is more favourable than that of monotherapy, due to the latter contributing to increased vasomotor symptoms and substantial bone mineral density (BMD) loss, as shown in a study.

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

05 Aug 2024

IVIG plus prednisolone does not help improve chances of pregnancy

04 Aug 2024 by

The use of intravenous immunoglobulin (IVIG) plus prednisolone does not appear to increase conception rates among women with recurrent pregnancy loss who are undergoing assisted reproductive technology (ART), according to a study.

IVIG plus prednisolone does not help improve chances of pregnancy

04 Aug 2024

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

04 Aug 2024

Bintrafusp alfa, an investigational first-in-class bifunctional fusion protein, appears to induce response in patients with recurrent or metastatic cervical cancer, according to a phase II study.

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

04 Aug 2024

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

03 Aug 2024

Placement of two etonogestrel implants instead of one appears to suppress ovulation and increase plasma etonogestrel exposure, thereby increasing contraceptive effectiveness in HIV-positive women on efavirenz-based antiretroviral therapy (ART).

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

03 Aug 2024

MIRV treatment effects sustained in PROC despite dose modifications

02 Aug 2024 by

In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.

MIRV treatment effects sustained in PROC despite dose modifications

02 Aug 2024

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

02 Aug 2024 by

In a combined analysis of 3 phase III randomized trials presented at ESHRE 2024, a single dose of 150 µg or 100 µg of corifollitropin alfa is found to provide an ovarian response equivalent to daily doses of 300 IU or 297 IU of follitropin beta, respectively, during a single IVF cycle

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

02 Aug 2024

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

01 Aug 2024 by

Women with ovarian hyperstimulation syndrome (OHSS) are at higher risk of experiencing postpartum haemorrhage, large birthweight, neonatal respiratory distress syndrome, and intraventricular haemorrhage, suggests a study presented at ESHRE 2024.

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

01 Aug 2024

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024 by

Hysterosalpingography (HSG) with an oil-based contrast medium yields a significantly higher rate of ongoing pregnancy and live birth than HSG with a water-soluble contrast medium, according to a study presented at ESHRE 2024.

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Female AYA cancer survivors: Are they at risk for adverse obstetric outcomes?

Female AYA cancer survivors: Are they at risk for adverse obstetric outcomes?

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

IVIG plus prednisolone does not help improve chances of pregnancy

IVIG plus prednisolone does not help improve chances of pregnancy

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

MIRV treatment effects sustained in PROC despite dose modifications

MIRV treatment effects sustained in PROC despite dose modifications

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

Infertile women may benefit from oil-based contrast during HSG

Infertile women may benefit from oil-based contrast during HSG

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus